Jefferies Upgrades ICON Public Limited Company (ICLR) to Buy from Hold

Core Viewpoint - ICON Public Limited Company (NASDAQ:ICLR) is currently viewed as a compelling investment opportunity despite ongoing internal accounting investigations and recent stock price adjustments by analysts [2][3]. Group 1: Analyst Upgrades - Jefferies analyst David Windley upgraded ICON from Hold to Buy, lowering the price target from $175 to $135, citing the stock's current valuation as "hard to ignore" [2]. - TD Cowen analyst Charles Rhyee also upgraded ICON from Hold to Buy, with a revised price target of $120, down from $183, suggesting that the recent selloff related to the internal accounting investigation is overdone [3]. Group 2: Internal Investigation - ICON disclosed an internal investigation initiated by the Audit Committee in October 2025, focusing on revenue recognition practices from fiscal years 2023 to 2025 [4]. - Preliminary findings suggest that revenue for 2023 and 2024 may have been overstated by less than 2% for each year, and the company expects to report one or more material weaknesses in internal controls [4]. Group 3: Company Overview - ICON provides outsourced development and commercialization services to pharmaceutical, biotechnology, and medical device companies globally [5].